Market Access

A roundtable explores how patient access needs are being measured, while also discussing the value of affordability in decision-making.

The partnership focuses on enhancing the patient experience by providing greater affordability and access to specialty meds.

NovoCare will offer the GLP-1 injection to cash-paying patients for a discounted $499 per month.

The injection for the treatment of psoriatic arthritis—among other indications—is a biosimilar to Stelara.

Digging a little deeper into the drug class phenomenon reveals some interesting takeaways on a smaller subgroup of users.

How chain and local closures are impacting healthcare access.

Finding the optimal balance in pharmacy benefit manager reform.

A look at the actionable steps needed to elicit change.

A cross-sectional study investigates the impact of Dobbs v Jackson’s Women’s Health Organization on national support and personal interest.

What factors influence their likelihood of receiving this form of obesity treatment?

A forum intended for HCPs, policy experts, and industry leaders addresses pressing obstacles facing this sector of the industry today.

A panel examines the gross-to-net bubble across various product mixes, how pricing impacts market access, and more.

Breakout session explores how direct-to-patient models shorten the time to diagnosis and therapy to improve patient outcomes.

Access Insights Conference delves into the latest obstacles, while mapping out potential solutions to address them.

A cohort study of cancer drugs analyzes where the priorities of pricing policies should lie.

Is the potential of a more formal policy integration for health issues and disease prevention a scary suggestion or a good idea?

While the program could be a good option for many, it's not a panacea.

A crash course on the bubble itself, including therapeutic areas most affected.

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Chase Feiger, MD, co-founder, Ostro, outlines the trends he expects to see over the next 10-15 years when it comes to the intersection of AI and life sciences.

The proposal aims to reduce out-of-pocket costs for a number of weight loss medications by 95%.

By 2050, study estimates that cancer incidence and mortality rates will nearly triple in low-Human Development Index countries, highlighting an urgent need for enhanced global cancer prevention, early detection, and treatment strategies to address growing disparities.

Tips for pharmacies with the reimbursement blues.

With a 26% decline in prescription drug plans from 2024 to 2025, navigating potential gaps and accessing care remains vital for low income patients.

Analysis finds that while basic Part D coverage costs have decreased by 4%, mid- and high-tier plans have seen hikes of 4% and 21%, respectively.

With today's pharmacy landscape shaken by unprecedented and wider disruption to healthcare support and delivery, community and independent entities strive to remain an integral cog in the mix.

Are SDOHs associated with Medicare, Medicaid, and private insurer spending?

Albert Thigpen, co-founder, Talentwise Consulting, discusses the valuable buckets pertaining to the PBM space.

Albert Thigpen, co-founder, Talentwise Consulting, explains how to use these tactics in order to anticipate the future US healthcare policy environment.

Albert Thigpen, co-founder, Talentwise Consulting, offers highlights of the drug commercialization panel that he participated in.

A panel dives into the current and future outlook of healthcare policies.